Alefacept for Severe Alopecia Areata: A Multicenter, Double-Blind, Randomized, Placebo-Controlled Clinical Trial

    November 2009 in “ Archives of dermatology ”
    Bruce Strober, Kavita Menon, Amy Mcmichael, Maria Hordinsky, Gerald G. Krueger, Jackie Panko, Kimberly Siu, Jonathan L. Lustgarten, Elizabeth K. Ross, Jerry Shapiro
    New to Alopecia Areata? There is a guide in the encyclopedia. Read the guide →
    Studysummary This study found that alefacept showed no significant improvement in treating severe alopecia areata compared to placebo over a 24-week period. Our plain-language summary of this paper — not a Tressless recommendation.
    A multicenter, double-blind, randomized, placebo-controlled clinical trial involving 45 individuals with severe alopecia areata (AA) assessed the efficacy of alefacept, a T-cell biologic inhibitor. Participants received alefacept for 12 weeks, but results showed no statistically significant improvement in the Severity of Alopecia Tool (SALT) score compared to the placebo group (P = .70). The study concluded that alefacept was ineffective for treating severe AA.
    Discuss this study in the Community →

    Research cited in this study

    2 / 2 results